Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 120

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 120
---
 adverse results from or delays                                                                                                           
 in preclinical studies and clinical trials of our product candidates, including as a result of clinical holds, safety events, enrollment 
 difficulties, or study protocol amendments;                                                                                              |

| ● | our decision to initiate a clinical                                                 
 trial, not to initiate a clinical trial or to terminate an existing clinical trial; |

| ● | adverse regulatory decisions,                                                                      
 including failure to receive regulatory approval of our drug to market for our product candidates; |

| ● | adverse developments concerning 
 our manufacturers;              |

| ● | our inability to obtain adequate                                                 
 product supply for any approved drug or inability to do so at acceptable prices; |

| ● | our inability to establish collaborations, 
 if needed;                                 |

| ● | our failure to commercialize 
 our product candidates;      |

| ● | additions or departures of key      
 scientific or management personnel; |

| ● | unanticipated serious safety                           
 concerns related to the use of our product candidates; |

| ● | introduction of new drugs by 
 our competitors;             |

| ● | announcements of significant                                                                          
 acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; |

| ● | any significant change in our 
 management;                   |

| ● | our ability to effectively manage 
 our growth;                       |

| ● | the size and growth of our initial 
 target markets;                    |

| ● | actual or anticipated variations 
 in quarterly operating results;  |

| ● | our cash position; |

| ● | our failure to meet the estimates                                                           
 and projections of the investment community or that we may otherwise provide to the public; |

| ● | the public’s response                                                                                       
 to press releases or other public announcements by us or third parties, including our filings with the SEC; |

| ● | publication of research reports                                                                                                             
 about us or our industry, or microbiome therapies in particular, or positive or negative recommendations or withdrawal of research coverage 
 by securities analysts;                                                                                                                     |

| ● | guidance, if any, that we provide                                                 
 to the public, any changes in this guidance or our failure to meet this guidance; |

| ● | changes in the market valuations 
 of similar companies;            |

| ● | overall performance of the equity 
 markets;                          |

| ● | sales of our Common Stock by           
 us or our stockholders, in the future; |

63

| ● | trading volume of our Common 
 Stock;                       |

| ● | investor perceptions of the                                                                        
 investment opportunity associated